NEW YORK – Apis Assay Technologies has signed a master collaboration agreement with Tampa, Florida-based Moffitt Cancer Center to determine the suitability of TROLL-2 and TROLL-3 long non-coding RNAs (lncRNA) as predictive biomarkers for cancer progression.